An observational study in Cultural Adaptation of Shoulder and Elbow PROMs, Definition of the Patients Acceptable Symptomatic State and Definition of the Minimal Important Difference, sponsored by Helsinki University Central Hospital. Status unknown at 1 site in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-28.
Sponsored by Helsinki University Central Hospital · Observational
The purpose of φ-PROMISE project is to carry out a cultural adaptation (translate into Finnish and validate) some of the most frequently used shoulder- and elbow-specific patient-reported outcome measures, PROMs. In addition, we aim to investigate which outcome measures are the most relevant for assessing the severity of complaints and treatment outcomes. Also, we will define the Patients Acceptable Symptomatic State (PASS) and the Minimal Important Difference (MID) of the individual outcome measures.
Helsinki University Central Hospital is the lead sponsor of 299 studies on the registry; 60 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Secondary care outpatient clinic
Exclusion Criteria:
Patients with shoulder problems presenting to the orthopaedic outpatient clinic of the Helsinki University Hospital
Procedure: Surgical or non-surgical treatment
Patients with elbow problems presenting to the orthopaedic outpatient clinic of the Helsinki University Hospital
Procedure: Surgical or non-surgical treatment
Surgical treatment (depending on diagnosis) Non-surgical treatment (such as exercise therapy, pain medication, watch and wait)
Validation
Assessment of inter- and intra- observer reliability of different outcome measures
Time frame: 2 weeks
PASS
Definition of the Patients Acceptable Symptomatic State for different outcomes
Time frame: 1 year
MID
Definition of the Minimal Important Difference for different outcomes
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helsinki University Central Hospital